Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?
The S&P/ASX 200 is set to fall after oil prices spiked on renewed US-Iran tensions. Here are today's top stories.
Land Rover has updated its Defender 4x4 with a new trim, a new bodykit, some new paint options… and cut a whopping 93bhp out ...
Generally speaking, most manufacturers aim to spruce up the appearance of a volume seller every three years or so - otherwise ...
An announcement from Crinetics Pharmaceuticals ( (CRNX)) is now available. On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals signed a definitive merger agreement under which Vertex ...
The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis ...
6hon MSN
Health care roundup: Market talk
Find insight on Eli Lilly, Vertex Pharmaceuticals and more in the latest Market Talks covering the health care sector.
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
Major indexes declined Tuesday, pulled lower by chip stocks, after beginning the week with gains. The Dow Jones Industrial ...
Casgevy is now approved in the U.S. for children with sickle cell as young as 2, becoming the first gene-editing therapy for ...
Kirkland & Ellis, Paul Weiss and Morrison & Foerster (MoFo) have scored roles in Vertex's $10bn acquisition of Crinetics, one ...
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results